Diabetes and Cancer: ADA/ACS Consensus Report


Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010 Jul;33(7):1674-85. PubMed PMID: 20587728; PubMed Central PMCID: PMC2890380. [Free full text]

A consensus statement from the American Diabetes Association and the American Cancer Society. A review of evidence concerning “the association between diabetes and cancer incidence or prognosis, risk factors common to both diabetes and cancer, possible biologic links between diabetes and cancer risk, and whether diabetes treatments influence risk of cancer or cancer prognosis.

Key findings and recommendations:

  • Diabetes (primarily type 2) is associated with increased risk for some cancers (liver, pancreas, endometrium, colon and rectum, breast, bladder). Diabetes is associated with reduced risk of prostate cancer. For some other cancer sites there appears to be no association or the evidence is inconclusive.
  • The association between diabetes and some cancers may partly be due to shared risk factors between the two diseases, such as aging, obesity, diet, and physical inactivity.
  • Possible mechanisms for a direct link between diabetes and cancer include hyperinsulinemia, hyperglycemia, and inflammation.
  • Healthful diets, physical activity, and weight management reduce risk and improve outcomes of type 2 diabetes and some forms of cancer and should be promoted for all.
  • Patients with diabetes should be strongly encouraged by their health care professionals to undergo appropriate cancer screenings as recommended for all people in their age and sex.
  • The evidence for specific drugs affecting cancer risk is limited, and observed associations may have been confounded by indications for specific drugs, effects on other cancer risk factors such as body weight and hyperinsulinemia, and the complex progressive nature of hyperglycemia and pharmacotherapy in type 2 diabetes.
  • Although still limited, early evidence suggests that metformin is associated with a lower risk of cancer and that exogenous insulin is associated with an increased cancer risk. Further research is needed to clarify these issues and evaluate if insulin glargine is more strongly associated with cancer risk compared with other insulins.
  • Cancer risk should not be a major factor in choosing between available diabetes therapies for the average patient. For selected patients with very high risk for cancer occurrence (or for recurrence of specific cancer types), these issues may require more careful consideration.

The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.